Recommended Reading on Pharmacotherapy

ESC Working Group on Cardiovascular Pharmacotherapy

Date

Title

• Date: 01/12/2024
  Title: Update on antithrombotic therapy and body mass. A Clinical consensus Statement of the ESC Working Group on Cardiovascular Pharmacotherapy and the ESC Working Group on Thrombosis.
• Date: 01/12/2024
  Title: Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis.
• Date: 01/12/2024
  Title: The ESC Working Group on Cardiovascular Pharmacotherapy: continuity through transformation.
• Date: 01/06/2024
  Title: The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease
• Date: 01/06/2024
  Title: Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
• Date: 01/12/2023
  Title: Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
• Date: 01/12/2023
  Title: The European Society of Cardiology working group on cardiovascular pharmacotherapy
• Date: 01/12/2023
  Title: Management of patients on antithrombotic therapy with severe infections
• Date: 08/08/2023
  Title: Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
• Date: 08/08/2023
  Title: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
• Date: 08/08/2023
  Title: Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
• Date: 01/02/2023
  Title: The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischaemic heart disease
• Date: 01/02/2023
  Title: Advancing medical education—a brief report by the ESC Working Group on Cardiovascular Pharmacotherapy
• Date: 01/02/2023
  Title: Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice
• Date: 04/07/2022
  Title: Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients
• Date: 04/07/2022
  Title: Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis
• Date: 04/07/2022
  Title: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 01/04/2022
  Title: β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction
• Date: 01/04/2022
  Title: Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients
• Date: 01/04/2022
  Title: Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing
• Date: 01/04/2022
  Title: Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis
• Date: 08/02/2022
  Title: Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters
• Date: 31/01/2022
  Title: Medication in adults after atrial switch for transposition of the great arteries: clinical practice and recommendations
• Date: 31/01/2022
  Title: Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 01/11/2021
  Title: Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting
• Date: 01/11/2021
  Title: Prescriber responsibility, predictors for initiation, and 20-year trends in use of non-aspirin non-steroidal anti-inflammatory drugs in patients with cardiovascular contraindications: a nationwide cohort study
• Date: 01/11/2021
  Title: Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
• Date: 01/09/2021
  Title: Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis
• Date: 01/09/2021
  Title: Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants
• Date: 01/09/2021
  Title: The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
• Date: 02/08/2021
  Title: Depressive symptoms and non-adherence to treatable cardiovascular risk factors’ medications in the CONSTANCES cohort
• Date: 02/08/2021
  Title: 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations
• Date: 02/08/2021
  Title: Subgroup analyses in randomized clinical trials: Value and limitations Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy
• Date: 06/05/2021
  Title: Update on management of hypokalemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 06/05/2021
  Title: Sodium–glucose co-transporter 2 inhibitors in heart failure
• Date: 06/05/2021
  Title: A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?
• Date: 22/03/2021
  Title: Left ventricular thrombosis: new perspectives on an old problem
• Date: 22/03/2021
  Title: A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
• Date: 22/03/2021
  Title: Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk—an inverse probability of treatment weighted study on 54 872 patients
• Date: 01/11/2020
  Title: The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management . Pierre Sabouret , Giuseppe Galati , Denis Angoulvant , Olga Germanova , Silvia Castelletti , Atul Pathak, Marco Metra , Alberto Margonato
• Date: 17/09/2020
  Title: Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF)
• Date: 01/09/2020
  Title: New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF Shinichi Goto, Shinya Goto, Karen S Pieper, Jean-Pierre Bassand, Alan John Camm ... European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 5, September 2020, Pages 301–309
• Date: 05/06/2020
  Title: Antihypertensive drugs in COVID-19 infection
• Date: 05/06/2020
  Title: Antihypertensive drugs in COVID-19 infection
• Date: 29/05/2020
  Title: Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs
• Date: 22/05/2020
  Title: Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease
• Date: 15/05/2020
  Title: Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial
• Date: 01/04/2020
  Title: Speculation is not evidence: antihypertensive therapy and COVID-19
• Date: 18/03/2020
  Title: Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk—an inverse probability of treatment weighted study on 54 872 patients
• Date: 17/03/2020
  Title: All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease
• Date: 01/03/2020
  Title: Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases Gianluigi Savarese, Martin F Reiner, Alicia Uijl, Domenico D’Amario, Stefan Agewall ... European Heart Journal
• Date: 02/10/2019
  Title: Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases
• Date: 21/09/2019
  Title: Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1
• Date: 08/08/2019
  Title: Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
• Date: 25/06/2019
  Title: PCSK9 and inflammation: a review of experimental and clinical evidence
• Date: 14/06/2019
  Title: Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis
• Date: 23/05/2019
  Title: Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
• Date: 15/05/2019
  Title: Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned GPI during primary percutaneous coronary intervention in acute myocardial infarction – a VALIDATE-SWEDEHEART substudy
• Date: 01/04/2019
  Title: Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
• Date: 01/04/2019
  Title: Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study
• Date: 29/03/2019
  Title: Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1
• Date: 28/01/2019
  Title: Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
• Date: 23/01/2019
  Title: Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study
• Date: 19/01/2019
  Title: Is P2Y12 inhibitor therapy associated with an increased risk of cancer?
• Date: 25/08/2018
  Title: The management of hypertensive emergencies
• Date: 07/08/2018
  Title: Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review
• Date: 23/07/2018
  Title: A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation
• Date: 27/02/2018
  Title: Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction
• Date: 21/02/2017
  Title: Gender differences in the effects of cardiovascular drugs